Cryoport, Inc.
CYRX · XNASCIK 1124524fmd_1N75FJAN39RHV3E34BT6W6R329Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2026, 66 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 8 | 12 | 20 | 34 | 79 | 223 | 237 | 169 | 157 | 176 |
| Cost of revenue | 5 | 6 | 9 | 17 | 42 | 126 | 133 | 93 | 87 | 93 |
| Gross profit | 3 | 6 | 10 | 17 | 36 | 97 | 104 | 75 | 70 | 83 |
| Provision for credit losses | – | – | – | – | – | 0 | 0 | 1 | – | – |
| Research and development | 1 | 1 | 2 | 4 | 9 | 17 | 16 | 18 | 18 | 17 |
| Selling, general and administrative | 11 | 13 | 17 | 31 | 57 | 98 | 120 | 108 | 110 | 103 |
| Total operating expenses | 12 | 14 | 19 | 35 | 66 | 114 | 136 | 176 | 191 | 120 |
| Operating income | (9) | (8) | (9) | (18) | (30) | (18) | (32) | (101) | (122) | (37) |
| Interest expense | 0 | 0 | 0 | 1 | 3 | 5 | 6 | 6 | 4 | 2 |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (4) | (0) | (1) | (1) | (3) | (256) | (3) | 16 | 17 | 5 |
| Income before taxes | (13) | (8) | (10) | (18) | (33) | (274) | (35) | (84) | (104) | (32) |
| Income tax expense | 0 | 0 | 0 | 0 | (0) | 2 | 2 | 0 | 0 | 2 |
| Net income from continuing operations | (13) | (8) | (10) | (18) | (33) | (276) | (37) | (85) | (105) | (34) |
| Net income | (13) | (8) | (10) | (18) | (33) | (276) | (37) | (100) | (115) | 78 |
| Net income to common shareholders | (13) | (8) | – | (18) | (75) | (284) | (45) | (108) | (123) | 70 |